Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $21.00 at Royal Bank Of Canada

Apellis Pharmaceuticals (NASDAQ:APLS) had its price target decreased by Royal Bank Of Canada from $22.00 to $21.00 in a research note issued to investors on Wednesday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

Several other analysts also recently issued reports on APLS. HC Wainwright boosted their price target on Apellis Pharmaceuticals from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald lowered their price objective on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. Needham & Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Wolfe Research assumed coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 6th. They issued a “peer perform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 29th. Twelve equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $32.61.

Apellis Pharmaceuticals Stock Down 3.2%

Shares of APLS opened at $21.42 on Wednesday. The firm has a market cap of $2.71 billion, a P/E ratio of 20.02 and a beta of 0.26. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. Apellis Pharmaceuticals has a 52 week low of $16.10 and a 52 week high of $30.48. The firm’s 50-day simple moving average is $23.13 and its 200 day simple moving average is $23.83.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.86. Apellis Pharmaceuticals had a return on equity of 9.31% and a net margin of 2.23%.The company had revenue of $199.91 million during the quarter, compared to analysts’ expectations of $199.28 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The business’s revenue was down 5.9% on a year-over-year basis. On average, analysts forecast that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Pascal Deschatelets sold 5,928 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $129,052.56. Following the completion of the sale, the insider owned 1,151,382 shares of the company’s stock, valued at $25,065,586.14. This represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel David O. Watson sold 7,832 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $170,502.64. Following the sale, the general counsel owned 88,531 shares in the company, valued at $1,927,319.87. The trade was a 8.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 120,537 shares of company stock valued at $2,608,532 over the last 90 days. 6.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its stake in Apellis Pharmaceuticals by 206.8% during the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after purchasing an additional 1,373 shares during the last quarter. Osaic Holdings Inc. lifted its position in shares of Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after buying an additional 1,570 shares during the last quarter. Allworth Financial LP boosted its stake in Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after buying an additional 857 shares in the last quarter. Quantbot Technologies LP bought a new position in Apellis Pharmaceuticals in the third quarter valued at about $64,000. Finally, EverSource Wealth Advisors LLC grew its position in Apellis Pharmaceuticals by 338.5% in the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock valued at $94,000 after acquiring an additional 4,191 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat EPS and slightly topped revenue expectations; management highlighted a strong new launch for EMPAVELI (sales up ~50%), which offsets some weakness in other products. This is the company press release/financial report. Apellis Q4 Results (GlobeNewswire)
• Positive Sentiment: HC Wainwright raised its price target to $48 and maintained a buy rating, signaling bullish analyst conviction around long-term upside tied to product launches. HC Wainwright PT Raise (Benzinga)
• Neutral Sentiment: Full earnings call transcript, slide deck and third‑party coverage are available — useful for digging into guidance, channel dynamics and management commentary but not new market-moving data by themselves. Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short-interest data in the feeds appears unreliable/zero (NaN/0 shares), so there’s no clear short-selling pressure signal to explain today’s move. (Data flagged as inconsistent across feeds.)
• Negative Sentiment: Some coverage flagged a wider-than-expected loss narrative and year-over-year revenue decline (~5.9% YoY); Syfovre sales slipped ~8%, which raises near-term growth concerns even though EPS beat. Zacks Earnings Coverage
• Negative Sentiment: Several brokers adjusted price targets downward or to neutral: RBC cut to $21 (sector perform) and Wedbush cut to $18 (neutral); Citigroup trimmed its target slightly to $44 but kept a buy rating — the mixed analyst actions add near-term selling pressure. Analyst Moves (Benzinga) TickerReport

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.